ANTHONY BIANCHI: Open Payments
NPI 1699201079 · HOOVER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,351 in 53 payments from 15 companies in 2025. Trend: 2023 $358 · 2024 $590 · 2025 $1,351
Food & beverage: $1,351
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 9 | $311 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $224 |
| Neurocrine BioSciences, Inc. | 6 | $148 |
| Axsome Therapeutics, Inc. | 2 | $138 |
| Lundbeck LLC | 5 | $108 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Alkermes, Inc. | 2 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $49 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
Products named: FANAPT, CAPLYTA, INGREZZA, Auvelity, ABILIFY MAINTENA, REXULTI, UZEDY, ARISTADA.
Industry payments across AL — which companies pay providers there.
